Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Soohyun LeeHeeyoung LeeEun Young KimPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2020)
This systematic review and conventional meta-analysis demonstrated the overall similarity of the long-term efficacy and safety of biosimilar rituximab to those of originator rituximab in RA and NHL patients by combining direct evidence from head-to-head trials. PROSPERO registration No. CRD42019125138.
Keyphrases
- diffuse large b cell lymphoma
- systematic review
- hodgkin lymphoma
- rheumatoid arthritis
- meta analyses
- chronic lymphocytic leukemia
- end stage renal disease
- ejection fraction
- newly diagnosed
- disease activity
- chronic kidney disease
- optic nerve
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- systemic lupus erythematosus
- patient reported outcomes